Health Plans Only · Claims Open

$180 Million Opioid Settlements for Health Plans — Allergan, Janssen, Teva, CVS, Walgreens and Walmart; Claims Due December 1, 2026

Published November 22, 2026

Health insurers, self-funded health plans and other third-party payors that paid for prescription opioids or opioid-related treatment for their members between January 1, 1996 and June 16, 2026 may qualify to claim a share of $180 million from the Allergan, Janssen, Teva, CVS, Walgreens and Walmart opioid third-party payor class action settlements. Individual consumers are not eligible, and claims close December 1, 2026.

Prescription pill bottle with spilled tablets and capsules

Current Status

Important: these settlements are for health plans and other third-party payors only. Individual patients and consumers are excluded from the class and cannot file.

Claims close December 1, 2026: online claims must be received and mailed claims postmarked by that date. The U.S. District Court for the Northern District of Ohio granted final approval to the Allergan, Janssen, Teva and pharmacy settlements on September 23, 2026. Payments have not started and no payment date has been announced.

Status Claims Open Third-party payors only · not individuals
Claim Deadline December 1, 2026 Received online or postmarked by this date
Estimated Payout Not yet determined Pro rata share of $180 million under the Plan of Allocation
Proof Required Yes Transactional claims data or covered-lives enrollment counts

What Changed Recently?

On September 23, 2026, the court granted final approval to the four settlements in the multidistrict opioid litigation, In re: National Prescription Opiate Litigation, No. 1:17-md-2804, before U.S. District Judge Dan A. Polster. The court had granted preliminary approval on June 16, 2026.

The third-party payor plaintiffs claim that drug manufacturers misrepresented the risks of long-term opioid use, that distributors did not properly monitor or report suspicious orders, and that pharmacies filled opioid prescriptions that were not written for legitimate medical purposes, leaving health plans to pay for opioid prescriptions and opioid use disorder treatment. The settling defendants deny the claims and deny any wrongdoing, and the court has not decided who is right.

Who Qualifies?

The class covers entities that, between January 1, 1996 and June 16, 2026, paid for or reimbursed opioid products for purposes other than resale, or paid for treatment, services or procedures related to opioid use, misuse, addiction or overdose, on behalf of their beneficiaries, insureds or members. The settlement website says third-party payors generally include health insurers, third-party administrators, HMOs, health and welfare plans paying from their own funds, and self-funded plans that contract with an insurer or administrator for prescription benefits.

The class expressly includes private contractors of Federal Employees Health Benefits plans, plans for self-insured local government entities that have not settled claims in MDL 2804, managed Medicaid plans, Medicare Part C and Part D plans, Taft-Hartley plans and ERISA plans.

Excluded are federal government entities; state and local government entities whose claims were released by an earlier settlement with the settling defendants; pharmacy benefit managers; consumers; fully insured plan sponsors; the settling defendants and their affiliates, officers, directors and employees and their immediate families; defendants in the coordinated opioid cases; and anyone who opted out by August 13, 2026.

How Much Can You Get?

The four settlements total $180 million: $10 million from Allergan, $40 million from Janssen, $45 million from Teva and $85 million from the settling pharmacies, CVS, Walgreens and Walmart. Interest is added, and court-approved attorneys’ fees (class counsel could seek up to 20% of the funds), expenses, service awards and administration costs are deducted. The rest is divided pro rata among third-party payors that file valid claims, under the Plan of Allocation posted on the settlement website. No per-claimant estimate has been published.

What Proof Is Required?

The claim form is built on the payor’s own data. The settlement website offers two filing templates: one for payors that have transactional claims data, with lists of the applicable NDC drug codes and ICD and HCPCS treatment codes, and one for payors that do not, which reports covered lives by state and year. A payor that cannot break covered lives down by state can report them by year. A payor that filed in the earlier MDL 2804 TPP class settlement with the settling distributors, or in the McKinsey TPP class settlement, can complete Section A and check a box in Section E to rely on its previous filing instead of resubmitting data.

What Is the Deadline?

December 1, 2026. Claims submitted online must be received, and claims sent by mail must be postmarked, on or before that date. The notice does not specify a time of day.

How Do You Take Action?

Third-party payors, or an authorized agent, can file through the File a Claim page of the official settlement website, which links to the online claim form, the printable claim form and the data templates. Contact options for the Notice and Claims Administrator, A.B. Data, are on the website’s contact page.

What Happens Next?

Before any money goes out, any appeals must be resolved and the administrator must finish processing claims and calculate distributions. Teva and two of the settling pharmacies are paying over time; Teva’s second payment is due March 1, 2028, which the notice says may affect when distributions are made. No payment date has been announced.

Sources and Verification



OCA’s overview of opioid class action settlements covers the wider litigation.

Questions

Can individual patients or consumers claim from the opioid third-party payor settlements?

No. Consumers are expressly excluded from the class. Only third-party payors, such as health insurers, HMOs, self-funded health and welfare plans and third-party administrators, that paid for opioid prescriptions or opioid-related treatment for their members can file.

Which health plans are excluded from the opioid TPP settlements?

Excluded are federal government entities, state and local government entities whose claims a prior settlement with the settling defendants already released, pharmacy benefit managers, fully insured plan sponsors, the settling defendants and their affiliates, and anyone who opted out by August 13, 2026.

Does a payor that filed in an earlier opioid TPP settlement have to file again?

It still has to submit a claim form, but the settlement website says a payor that filed in the earlier TPP class settlement with the settling distributors in MDL 2804, or in the McKinsey TPP class settlement, can complete Section A of the form and check a box in Section E to rely on its previous filing instead of resubmitting data.

When will opioid TPP settlement payments be made?

No date has been announced. The court granted final approval on September 23, 2026, but any appeals must be resolved and claims processed first, and Teva and two of the settling pharmacies pay over time. Teva's second payment, for example, is due March 1, 2028.

For more class actions keep scrolling below.
Settlement Amount $180 million Allergan $10M · Janssen $40M · Teva $45M · CVS, Walgreens & Walmart $85M
Case Title In re: National Prescription Opiate Litigation
Case Number 1:17-md-2804 (MDL 2804)
Court U.S. District Court, Northern District of Ohio
Final Approval Hearing September 23, 2026 Final approval granted
Administrator A.B. Data, Ltd. Notice and Claims Administrator
Official Website TPP Opioid Settlement

More Prescription Drug Settlements